Table of Contents

Poster Presentations

• Poster Presentations

  Abstract A1: Functional significance of miR-10b in tamoxifen resistance of breast cancer cells

  Aamir Ahmad, Kaladhar B. Reddy and Fazlul H. Sarkar

  Clin Cancer Res May 15 2012 18 (10 Supplement) A1-A1; DOI:10.1158/1078-0432.MECHRES-A1

  
  
• Poster Presentations

  Abstract A2: Selective inhibition of mTORC1/mTORC2 sensitizes prostate cancer cells to the effects of AR or IGF-1R/IR antagonists, providing an approach to overcome intrinsic mechanisms of resistance

  Matthew O'Connor, Elizabeth Buck, Stuart Thomson, David Epstein, Miglarese Mark and Sharon Barr

  Clin Cancer Res May 15 2012 18 (10 Supplement) A2-A2; DOI:10.1158/1078-0432.MECHRES-A2

  
  
• Poster Presentations

  Abstract A3: mTOR signaling and tamoxifen response in postmenopausal breast cancer

  Josefine Bostner, Elin Karlsson, Muneeswaran Jayachandra Pandiyan, Tommy Fornander and Bo Nordenskjöld

  Clin Cancer Res May 15 2012 18 (10 Supplement) A3-A3; DOI:10.1158/1078-0432.MECHRES-A3

  
  
• Poster Presentations

  Abstract A4: A novel class of selective ERα degraders acts as full antagonists/ inverse agonists and displays efficacy in pre-clinical models of endocrine-resistant breast cancer and endometrial cancer

  Beatrice Darimont, Ninh Lu, John Sensintaffar, Kyoung-Jin Lee, Anna Aparicio, Joshua Kaufman, Eric Bischoff, Peter Rix, Rich Heyman, Nicholas Smith, Jeffrey Hager, James Joseph, Katherine Grillot, Jing Qian, Shao Gang, Steven Govek, Johnny Nagasawa, Andiliy Lai and Mehmet Kahraman

  Clin Cancer Res May 15 2012 18 (10 Supplement) A4-A4; DOI:10.1158/1078-0432.MECHRES-A4

  
  
• Poster Presentations

  Abstract A5: Can activation of the UPR lead to Trastuzumab resistance?

  Sreekanth Kumandan, Navin R. Mahadevan, Alexandra DeLaney and Maurizio Zanetti

  Clin Cancer Res May 15 2012 18 (10 Supplement) A5-A5; DOI:10.1158/1078-0432.MECHRES-A5

  
  
• Poster Presentations

  Abstract A6: Sustained MAPK signaling contributes to reduced sensitivity to lapatinib

  Sylvia S. Gayle and Rita Nahta

  Clin Cancer Res May 15 2012 18 (10 Supplement) A6-A6; DOI:10.1158/1078-0432.MECHRES-A6

  
  
• Poster Presentations

  Abstract A7: A novel class of selective estrogen receptors degraders regresses tumors in pre-clinical models of endocrine-resistant breast cancer

  Beatrice Darimont, Steven Govek, Nihn Lu, Johnny Nagasawa, Rene Prudente, Jing Qian, John Sensintaffar, Gang Shao, Richard Heyman, Peter Rix, Nicholas Smith, Jeffrey Hager, James Joseph, Katherine Grillot, Anna Aparicio, Eric Bischoff, Mehmet Kahraman, Josh Kaufman, Andiliy Lai and Kyoung-Jin Lee

  Clin Cancer Res May 15 2012 18 (10 Supplement) A7-A7; DOI:10.1158/1078-0432.MECHRES-A7

  
  
• Poster Presentations

  Abstract A8: Combating adaptive ERBB3-mediated resistance to ERBB2 inhibitors: In Silico optimization of MM-111 and lapatinib dosing regimens

  Daniel C. Kirouac, Johanna Lahdenranta, Ryan Overland, Jinyan Du, Charlotte McDonagh, Ulrik Nielson and Mathew Onsum

  Clin Cancer Res May 15 2012 18 (10 Supplement) A8-A8; DOI:10.1158/1078-0432.MECHRES-A8

  
  
• Poster Presentations

  Abstract A9: The cocaine and amphetamine-regulated transcript (CART) is an independent prognostic factor in lymph node-negative breast cancer and predicts outcome in tamoxifen treated patients

  Darran O'Connor, Donal Brennan, Henriette Laursen, Rene Bernards, John Crown, Karin Jirstrom and William Gallagher

  Clin Cancer Res May 15 2012 18 (10 Supplement) A9-A9; DOI:10.1158/1078-0432.MECHRES-A9

  
  
• Poster Presentations

  Abstract A10: Peroxiredoxin-1 and oxidative stress: Controlling the balance between oncogenic and endocrine signalling in estrogen receptor-positive breast cancer

  Patrick C. O'Leary, Donal J. Brennan, John Crown, William M. Gallagher, Radoslaw Zagozdzon, Yue Fan, Bryan T. Hennessy, Ana-Maria Gonzalez-Angulo, Gordon Mills, Fredrik Ponten, Karin Jirstrom, Mathias Uhlen and Darran O'Connor

  Clin Cancer Res May 15 2012 18 (10 Supplement) A10-A10; DOI:10.1158/1078-0432.MECHRES-A10

  
  
• Poster Presentations

  Abstract A12: Identification of Nrdp1 as a novel androgen receptor transcription target differentially regulated in androgen-dependent and independent prostate cancer

  Rosalinda M. Savoy, Liqun Chen, Dean Troyer, Paramita Ghosh, William Fry, Kermit Carraway, Slama Siddiqui, Frank Melgoza, Mohana Roy, Ryan E. Beggs, Maitreyee K. Jathal, Swagata Bose, Yu Wang and Roble Bedolla

  Clin Cancer Res May 15 2012 18 (10 Supplement) A12-A12; DOI:10.1158/1078-0432.MECHRES-A12

  
  
• Poster Presentations

  Abstract A14: Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer

  Aoife Ward, Aleksandra Balwierz, Jitao David Zhang, Moritz Kueblbeck, Stefan Wiemann, Thomas Hielscher, Yudi Pawitan and Ozgur Sahin

  Clin Cancer Res May 15 2012 18 (10 Supplement) A14-A14; DOI:10.1158/1078-0432.MECHRES-A14

  
  
• Poster Presentations

  Abstract A16: Molecular mechanisms of EGFR therapy resistance in breast cancer cells

  Linette Castillo-Pichardo, Luis D. Borrero-Garcia, Roxana S. Redis, George A. Calin, Luis A. Cubano and Suranganie Dharmawardhane

  Clin Cancer Res May 15 2012 18 (10 Supplement) A16-A16; DOI:10.1158/1078-0432.MECHRES-A16

  
  
• Poster Presentations

  Abstract A17: Loss of DEPTOR increases resistance to EGFR tyrosine kinase inhibitors by upregulating EGFR and MAPK signaling

  Catherine F. Cowell, Elza C. De Bruin, Michael Howell and Julian Downward

  Clin Cancer Res May 15 2012 18 (10 Supplement) A17-A17; DOI:10.1158/1078-0432.MECHRES-A17

  
  
• Poster Presentations

  Abstract A18: Reduced NF1 expression in resistance to EGF receptor inhibitory drugs in lung adenocarcinoma

  Elza de Bruin, Catherine Cowell, Michael Howell, Harold Varmus, Katerina Politi and Julian Downward

  Clin Cancer Res May 15 2012 18 (10 Supplement) A18-A18; DOI:10.1158/1078-0432.MECHRES-A18

  
  
• Poster Presentations

  Abstract A19: A qPCR assay, OncoScore Colon, predicts resistance to cetuximab in formalin-fixed, paraffin-embedded colorectal cancer tissue independent of KRAS status

  Sean Eddy, Byung-In Lee, Teresa Macarulla, Josep Tabernero, Joseph Monforte, Daniel R. Rhodes, Paul Williams, Mark Tomilo, Seth Sadis, Peter Wyngaard, Lien Vo, Kahuku Oades, Hyunsoo Kim and Yipeng Wang

  Clin Cancer Res May 15 2012 18 (10 Supplement) A19-A19; DOI:10.1158/1078-0432.MECHRES-A19

  
  
• Poster Presentations

  Abstract A20: DARPP-32-mediated EGFR protein stability leads to gefitinib resistance in gastric cancer

  Shoumin Zhu, Abbes Belkhiri and Wael El-Rifai

  Clin Cancer Res May 15 2012 18 (10 Supplement) A20-A20; DOI:10.1158/1078-0432.MECHRES-A20

  
  
• Poster Presentations

  Abstract A21: Dual-kinase inhibition of EGFR/ERBB2 as a therapeutic strategy in prostate cancer

  Maitreyee K. Jathal, Benjamin A. Mooso, Leandro S. D'Abronzo and Paramita M. Ghosh

  Clin Cancer Res May 15 2012 18 (10 Supplement) A21-A21; DOI:10.1158/1078-0432.MECHRES-A21

  
  
• Poster Presentations

  Abstract A22: Effectiveness of ErbB inhibitors in the treatment of bladder cancer

  Benjamin A. Mooso and Paramita M. Ghosh

  Clin Cancer Res May 15 2012 18 (10 Supplement) A22-A22; DOI:10.1158/1078-0432.MECHRES-A22

  
  
• Poster Presentations

  Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer

  Ken Takezawa, Mary Ann Melnick, Greg Riely, Mark Kris, Vincent Miller, Marc Ladanyi, Katerina Politi, William Pao, Valentina Pirazzoli, Xiaoling Song, Maria Arcila, Elisa De Stanchina, Kadoaki Ohashi, Yelena Janjigian, Paula Spitzler and Caroline Nebhan

  Clin Cancer Res May 15 2012 18 (10 Supplement) A23-A23; DOI:10.1158/1078-0432.MECHRES-A23

  
  
• Poster Presentations

  Abstract A24: Fibronectin-mediated activation of Stat3 facilitates the resistance of triple negative breast cancer to EGFR-targeted therapies

  Michael K. Wendt, Nikolas Balanis, Cathleen Carlin and William Schiemann

  Clin Cancer Res May 15 2012 18 (10 Supplement) A24-A24; DOI:10.1158/1078-0432.MECHRES-A24

  
  
• Poster Presentations

  Abstract A25: Uncommon mutation types of Epidermal Growth Factor Receptor (EGFR) and tyrosine kinase inhibitor response in non-small cell lung carcinoma

  Maria P. Wong, Victor H.F. Lee, Rebecca M.W. Yeung, Vicky P.C. Tin, Kit Chi Choy and Jing Liu

  Clin Cancer Res May 15 2012 18 (10 Supplement) A25-A25; DOI:10.1158/1078-0432.MECHRES-A25

  
  
• Poster Presentations

  Abstract A27: PI3K/Akt pathway-dependent and -independent mechanisms of resistance to EGFR tyrosine kinase inhibitors in glioblastoma

  Jill Wykosky, Webster Cavenee and Frank Furnari

  Clin Cancer Res May 15 2012 18 (10 Supplement) A27-A27; DOI:10.1158/1078-0432.MECHRES-A27

  
  
• Poster Presentations

  Abstract A29: Different PIK3CA activation mutations can lead to distinct signaling mechanisms and EGFR inhibitor sensitivities in colorectal cancer cells

  Matthew J. Wong, Marie-Claire Wagle, Garret Hampton and Yibing Yan

  Clin Cancer Res May 15 2012 18 (10 Supplement) A29-A29; DOI:10.1158/1078-0432.MECHRES-A29

  
  
• Poster Presentations

  Abstract A31: Roles of Nogo-B receptor (NgBR) in regulating Ras translocation and modulating breast cancer cell sensitivity to chemotherapeutic drug and irradiation

  Baofeng Zhao, Zhong Liu, Suresh Kumar and Robert Q. Miao

  Clin Cancer Res May 15 2012 18 (10 Supplement) A31-A31; DOI:10.1158/1078-0432.MECHRES-A31

  
  
• Poster Presentations

  Abstract A32: Notch signaling regulates recurrence in a model of HER2 targeted therapy

  Daniel L. Abravanel, Christopher J. Sterner, Tien-chi Pan, George K. Belka and Lewis A. Chodosh

  Clin Cancer Res May 15 2012 18 (10 Supplement) A32-A32; DOI:10.1158/1078-0432.MECHRES-A32

  
  
• Poster Presentations

  Abstract A33: Modeling clinical resistance to RAF inhibitors in an in vivo melanoma model provides insights into prevention of resistance

  Meghna Das Thakur, Fernando Salangsang, Nancy Pryer, Martin McMahon and Darrin Stuart

  Clin Cancer Res May 15 2012 18 (10 Supplement) A33-A33; DOI:10.1158/1078-0432.MECHRES-A33

  
  
• Poster Presentations

  Abstract A36: Doxorubicin loaded lactoferrin nanoparticles: Treatment of hepatocellular carcinoma in rats induced by diethylnitrosamine

  Kishore Golla, Bhaskar Cherukuvada, Ahmed Farhan and Anand Kumar Kondapi

  Clin Cancer Res May 15 2012 18 (10 Supplement) A36-A36; DOI:10.1158/1078-0432.MECHRES-A36

  
  
• Poster Presentations

  Abstract A37: Anti-telomerase therapy provokes ALT and mitochondrial adaptive mechanism in cancer

  Jian Hu, Sarah Hwang, Adam Boutin, Alan Wang, Lynda Chin, Marc Liesa, Orian Shiriha and Ronald DePinho

  Clin Cancer Res May 15 2012 18 (10 Supplement) A37-A37; DOI:10.1158/1078-0432.MECHRES-A37

  
  
• Poster Presentations

  Abstract A38: Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas

  Valentina Pirazzoli, Ken Takezawa, Elisa de Stanchina, William Pao and Katerina Politi

  Clin Cancer Res May 15 2012 18 (10 Supplement) A38-A38; DOI:10.1158/1078-0432.MECHRES-A38

  
  
• Poster Presentations

  Abstract A39: The exploration of novel strategy for treatment of pancreactic ductal adenocarcinoma targeting tumor microenvironment with multi-kinase inhibitors

  Motohisa Tada, Fumio Imazeki, Masao Omata, Harold L. Moses, Osamu Yokosuka, Hideaki Ijichi, Fumihiko Kanai, Yoshinari Asaoka, Dai Mohri, Koji Miyabayashi, Tsuneo Ikenoue, Rintarou Mikata and Katsunobu Tawada

  Clin Cancer Res May 15 2012 18 (10 Supplement) A39-A39; DOI:10.1158/1078-0432.MECHRES-A39

  
  
• Poster Presentations

  Abstract A41: Developing a mouse model of melanoma to identify drug resistance mechanisms

  James P. Robinson, Sheri L. Holmen and Matthew VanBrocklin

  Clin Cancer Res May 15 2012 18 (10 Supplement) A41-A41; DOI:10.1158/1078-0432.MECHRES-A41

  
  
• Poster Presentations

  Abstract A42: Sensitivity and resistance to a p-AKT inhibitor in an erlotinib-sensitive model for lung cancer

  Rajaa El Meskini, Philip L. Martin, Michelle Gumprecht, Alan Kulaga, Theresa Guerin, Maureen Baran, Anthony J. Iacovelli, Terry Van Dyke and Zoe Weaver

  Clin Cancer Res May 15 2012 18 (10 Supplement) A42-A42; DOI:10.1158/1078-0432.MECHRES-A42

  
  
• Poster Presentations

  Abstract A43: The Pi3K inhibitor GSK2126458 is highly toxic in breast ductal carcinoma

  Alia Albawardi, Saeeda Almarzooqi, Mohamed Al Bashir and Abdul-Kader Souid

  Clin Cancer Res May 15 2012 18 (10 Supplement) A43-A43; DOI:10.1158/1078-0432.MECHRES-A43

  
  
• Poster Presentations

  Abstract A44: The Pi3K inhibitor GSK2126458 is highly toxic in ovarian dysgerminoma

  Saeeda Almarzooqi, Alia Albawardi and Abdul-Kader Souid

  Clin Cancer Res May 15 2012 18 (10 Supplement) A44-A44; DOI:10.1158/1078-0432.MECHRES-A44

  
  
• Poster Presentations

  Abstract A45: Signaling Events Associated with Cytoprotective Induction of Nitric Oxide Synthase in a Photodynamic Therapy Model

  Reshma Bhowmick and Albert W. Girotti

  Clin Cancer Res May 15 2012 18 (10 Supplement) A45-A45; DOI:10.1158/1078-0432.MECHRES-A45

  
  
• Poster Presentations

  Abstract A46: Tumor P-glycoprotein Correlates with Efficacy of PF-03758309 Against In Vitro and In Vivo models of Colorectal Cancer

  Erica L. Bradshaw-Pierce, Todd M. Pitts, Kelly L. McPhillips, Daniel L. Gustafson, Aik-Choon Tan, Leslie Nguyen, Mark West, Timothy Fisher, Brion W. Murray and S. Gail Eckhardt

  Clin Cancer Res May 15 2012 18 (10 Supplement) A46-A46; DOI:10.1158/1078-0432.MECHRES-A46

  
  
• Poster Presentations

  Abstract A47: Inhibition of Rho kinase signaling in angiosarcomas leads to decreased tumor growth and invasiveness, but enhanced resistance to standard chemotherapeutics

  Dianne Courtenay Mitchell and Brad Allen Bryan

  Clin Cancer Res May 15 2012 18 (10 Supplement) A47-A47; DOI:10.1158/1078-0432.MECHRES-A47

  
  
• Poster Presentations

  Abstract A49: Combination of bendamustine and the HDAC inhibitor entinostat enhances apoptosis and DNA damage response in multiple myeloma cells

  Bo Cai, Jingcao Huang, Choon-Kee Lee and Bolin Liu

  Clin Cancer Res May 15 2012 18 (10 Supplement) A49-A49; DOI:10.1158/1078-0432.MECHRES-A49

  
  
• Poster Presentations

  Abstract A50: Development of a quantitative RON SRM Assay for use in formalin fixed tumor tissues

  Todd Hembrough, Wei-Li Liao, Les Henderson, Peng Xu, Jon Burrows and Daniel Catenacci

  Clin Cancer Res May 15 2012 18 (10 Supplement) A50-A50; DOI:10.1158/1078-0432.MECHRES-A50

  
  
• Poster Presentations

  Abstract A51: Antiproliferative activity of F14512, a novel polyamine-vectorized drug, on multidrug resistant cancer cells

  Laurent Créancier, Nicolas Guilbaud, Jean-Philippe Annereau, Viviane Brel, Marie-Laure Marionneau-Brossard, Vanessa Offrete, Jérôme Verdier, Karine André, Emmanuel Fournier, Yves Guminski and Anna Kruczynski

  Clin Cancer Res May 15 2012 18 (10 Supplement) A51-A51; DOI:10.1158/1078-0432.MECHRES-A51

  
  
• Poster Presentations

  Abstract A52: Comparison of the efficacy of different mTOR inhibitors for the treatment of prostate cancer

  Leandro Salati D'Abronzo, Ryan Beggs, Swagata Bose and Paramita Ghosh

  Clin Cancer Res May 15 2012 18 (10 Supplement) A52-A52; DOI:10.1158/1078-0432.MECHRES-A52

  
  
• Poster Presentations

  Abstract A53: Bayesian Network Inference Modeling Reveals Novel Regulators of Cell Cycle Progression and Survival

  Rina Gendelman, Heming Xing, Preeti Sarde, Olga K. Mirzoeva, Heidi Feiler, Joe W. Gray, Paul McDonagh, Iya Khalil and W. Michael Korn

  Clin Cancer Res May 15 2012 18 (10 Supplement) A53-A53; DOI:10.1158/1078-0432.MECHRES-A53

  
  
• Poster Presentations

  Abstract A54: Potential mechanisms of resistance to targeted agents in human clear cell renal cell carcinoma

  Adrian G. Grozav, Susan A.J. Vaziri, Koegle R. Eric, Dale R. Grabowski, Ronald M. Bukowski, Mahrukh K. Ganapathi and Ram N. Ganapathi

  Clin Cancer Res May 15 2012 18 (10 Supplement) A54-A54; DOI:10.1158/1078-0432.MECHRES-A54

  
  
• Poster Presentations

  Abstract A56: Canine Mast Cell Tumor and Toceranib Phosphate (Palladia™): Development of a Spontaneous Canine Model of Kinase Inhibitor Resistance

  Charles H.C. Halsey, Barbara J. Rose, Daniel L. Gustafson and Douglas H. Thamm

  Clin Cancer Res May 15 2012 18 (10 Supplement) A56-A56; DOI:10.1158/1078-0432.MECHRES-A56

  
  
• Poster Presentations

  Abstract A57: Chondroitin sulfate proteoglycan 4(CSPG4) Mediates Melanoma Cell Survival During PI3K and mTOR Inhibition

  Sehrish Javaid, Leah E. Colvin Wanshura and Arkadiusz Z. Dudek

  Clin Cancer Res May 15 2012 18 (10 Supplement) A57-A57; DOI:10.1158/1078-0432.MECHRES-A57

  
  
• Poster Presentations

  Abstract A60: Targeting p38 MAPK Signaling Pathway in Docetaxel Resistant Prostate Cancer

  Weijuan Li

  Clin Cancer Res May 15 2012 18 (10 Supplement) A60-A60; DOI:10.1158/1078-0432.MECHRES-A60

  
  
• Poster Presentations

  Abstract A61: Profile of Ponatinib, BGJ398, AZ4547 and DCC-2036 against FGFR2 Mutations identified in a Dovitinib Resistance BaF3 Screen

  David Loch, Sara Byron, Andreas Wortman, Huaibin Chen, Moosa Mohammadi and Pamela Pollock

  Clin Cancer Res May 15 2012 18 (10 Supplement) A61-A61; DOI:10.1158/1078-0432.MECHRES-A61

  
  
• Poster Presentations

  Abstract A62: The Bcl-2 associated athanogene 5 binds the molecular chaperone GRP78/BiP and increases chemoresistance in prostate cancer cells

  Anja Bruchmann, Corinna Roller, Tamara Vanessa Walther, Andrew Cato and Danilo Maddalo

  Clin Cancer Res May 15 2012 18 (10 Supplement) A62-A62; DOI:10.1158/1078-0432.MECHRES-A62

  
  
• Poster Presentations

  Abstract A64: NFκB-IκBα Interaction: A Mechanism of Resistance to Cisplatin in Non Small Cell Lung Cancer (NSCLC)

  Susan Heavey, Martin Barr, Peter Godwin, Connla Edwards, Ken O'Byrne and Kathy Gately

  Clin Cancer Res May 15 2012 18 (10 Supplement) A64-A64; DOI:10.1158/1078-0432.MECHRES-A64

  
  
• Poster Presentations

  Abstract A65: Combinational siRNA silencing of MCL-1 and P-gp enhances the apoptotic response in Human Breast Cancer Cells

  Hamidreza Montazeri Aliabadi and Hasan Uludag

  Clin Cancer Res May 15 2012 18 (10 Supplement) A65-A65; DOI:10.1158/1078-0432.MECHRES-A65

  
  
• Poster Presentations

  Abstract A66: Galectin-1 expression correlated with mesenchymal differentiation and resistance to chemotherapy in carcinoma cells

  Lucile Astorgues-Xerri, Eric Raymond, Sandrine Faivre, Caroline Halimi, Annemilai Tijeras-Raballand, Maria Eugenia Riveiro, Sebastien Albert, Maria Serova, Anne Couvelard, Muriel Hourseau and Armand de Gramont

  Clin Cancer Res May 15 2012 18 (10 Supplement) A66-A66; DOI:10.1158/1078-0432.MECHRES-A66

  
  
• Poster Presentations

  Abstract A68: Tumor cell dedifferentiation into endothelial cells and resistance to sunitinib in renal carcinoma models

  Maria Serova, Annemilai Tijeras-Raballand, Celia Dos Santos, Maria Eugenia Riveiro, Armand de Gramont, Sandrine Faivre and Eric Raymond

  Clin Cancer Res May 15 2012 18 (10 Supplement) A68-A68; DOI:10.1158/1078-0432.MECHRES-A68

  
  
• Poster Presentations

  Abstract B1: Dual mTORC1/mTORC2 inhibition limits tumor growth, VEGF production and vascular regrowth

  Sharon Barr, Beverly L. Falcon, Prafulla C. Ghokale, Jeyling Chou, Jennifer Fogarty, Philippe Depeille, Mark Miglarese and David M. Epstein

  Clin Cancer Res May 15 2012 18 (10 Supplement) B1-B1; DOI:10.1158/1078-0432.MECHRES-B1

  
  
• Poster Presentations

  Abstract B2: Supplementation of dietary fish oil induces apoptosis through activation of PPARγ and involves inhibition of angiogenesis in colon cancer

  Shevali Kansal, Anjana K. Negi and Navneet Agnihotri

  Clin Cancer Res May 15 2012 18 (10 Supplement) B2-B2; DOI:10.1158/1078-0432.MECHRES-B2

  
  
• Poster Presentations

  Abstract B3: Angiotensin IV-Related Hepatocyte Growth Factor Antagonists act as Anti-Angiogenic Anti-Cancer Agents

  Leen H. Kawas, Brandi C. Ward, Chromewell Mojica, John W. Wright and Joseph W. Harding

  Clin Cancer Res May 15 2012 18 (10 Supplement) B3-B3; DOI:10.1158/1078-0432.MECHRES-B3

  
  
• Poster Presentations

  Abstract B4: Everolimus inhibits invasion and angiogenesis in a KRAS-mutated mesenchymal-differentiated colorectal cancer xenografts

  Annemilai Tijeras-Raballand, Celia Dos Santos, Maria Serova, Maria Eugenia Riveiro, Armand de Gramont, Sandrine Faivre and Eric Raymond

  Clin Cancer Res May 15 2012 18 (10 Supplement) B4-B4; DOI:10.1158/1078-0432.MECHRES-B4

  
  
• Poster Presentations

  Abstract B5: CpG-siRNA conjugates: Overcoming cancer immunoresistance

  Sergey Nechaev, Qifang Zhang, Piotr Swiderski and Marcin Kortylewski

  Clin Cancer Res May 15 2012 18 (10 Supplement) B5-B5; DOI:10.1158/1078-0432.MECHRES-B5

  
  
• Poster Presentations

  Abstract B6: PEGPH20 depletion of pericellular hyaluronan sensitizes high hyaluronan-producing tumor cells in antibody-dependent cell-mediated cytotoxicity

  Netai C. Singha, Ping Jiang, Susan Zimmerman, Robert Connor, Gregory I. Frost, Zhongdong Huang and H. Michael Shepard

  Clin Cancer Res May 15 2012 18 (10 Supplement) B6-B6; DOI:10.1158/1078-0432.MECHRES-B6

  
  
• Poster Presentations

  Abstract B7: Annexin V inhibits local but not systemic murine fibrosarcoma growth by blocking phosphatidylserine

  Maen Masadeh, Chaobo Yin and Joel Shilyansky

  Clin Cancer Res May 15 2012 18 (10 Supplement) B7-B7; DOI:10.1158/1078-0432.MECHRES-B7

  
  
• Poster Presentations

  Abstract B8: FOXD3 enhances expression of ERBB3 and promotes resistance to vemurafenib

  Kevin J. Basile, Ethan V. Abel and Andrew E. Aplin

  Clin Cancer Res May 15 2012 18 (10 Supplement) B8-B8; DOI:10.1158/1078-0432.MECHRES-B8

  
  
• Poster Presentations

  Abstract B9: Activated MAPK Pathway Mediates Resistance to Romidepsin via Bim Degradation in Romidepsin-Selected HuT 78 Cells

  Arup Chakraborty, Robert Robey, Jean-Pierre Gillet, Victoria Luchenko, Richard Piekarz, Michael Gottesman, Nathan Collie and Susan Bates

  Clin Cancer Res May 15 2012 18 (10 Supplement) B9-B9; DOI:10.1158/1078-0432.MECHRES-B9

  
  
• Poster Presentations

  Abstract B10: Overcoming resistance to B-Raf targeting agents using LPD nanotechnology

  Chin-Ying Chung, Yuhua Wang, Wei-Yun Sheng, Yu-Cheng Tseng, Taryn Dick, Leaf Huang and Gavin Robertson

  Clin Cancer Res May 15 2012 18 (10 Supplement) B10-B10; DOI:10.1158/1078-0432.MECHRES-B10

  
  
• Poster Presentations

  Abstract B12: PTEN modulates sensitivity to a novel ERK inhibitor in BRAFV600E-mutant melanomas

  Clemens Krepler, Meenhard Herlyn, Jessie Villanueva, Ahmed Samatar, Yuhao Chen, Molly Halloran, Minu Samanta, Xu He, Adina Vultur, Bradley Wubbenhorst and Katherine Nathanson

  Clin Cancer Res May 15 2012 18 (10 Supplement) B12-B12; DOI:10.1158/1078-0432.MECHRES-B12

  
  
• Poster Presentations

  Abstract B13: Modeling BRAF inhibitor resistance in genetically engineered mouse models of melanoma

  Lawrence N. Kwong, Shan Jiang and Lynda Chin

  Clin Cancer Res May 15 2012 18 (10 Supplement) B13-B13; DOI:10.1158/1078-0432.MECHRES-B13

  
  
• Poster Presentations

  Abstract B14: Inherent resistance to BRAF inhibitors in BRAFV600E colorectal tumors is driven by ligand-dependent activation of the EGFR pathway

  Ivana Yen, Bonnie Liu, Hartmut Koeppen, Georgia Hatzivassiliou, Shiva Malek, Kyung Song, Patricia Pacheco, Leanne Berry Ross, Stephen Gould, Stephen Schmidt, Joachim Rudolph, Lori Friedman and Marcia Belvin

  Clin Cancer Res May 15 2012 18 (10 Supplement) B14-B14; DOI:10.1158/1078-0432.MECHRES-B14

  
  
• Poster Presentations

  Abstract B15: The pan-BCR-ABL inhibitor ponatinib inhibits viability of gatekeeper mutant BCR-ABL^T315I cells with greater potency than a nilotinib/MEK inhibitor combination

  Alexa B. Schrock, Joseph M. Gozgit and Victor Rivera

  Clin Cancer Res May 15 2012 18 (10 Supplement) B15-B15; DOI:10.1158/1078-0432.MECHRES-B15

  
  
• Poster Presentations

  Abstract B17: Mechanisms of resistance of BRAF fusions to first generation selective BRAF inhibitors

  Angela Jae Sievert, Shih-Shan Lang, Phillip B. Storm and Adam C. Resnick

  Clin Cancer Res May 15 2012 18 (10 Supplement) B17-B17; DOI:10.1158/1078-0432.MECHRES-B17

  
  
• Poster Presentations

  Abstract B19: The HSP90 inhibitor, AT13387, is effective against multiple mechanisms of kinase inhibitor resistance

  Ana Rodriguez-Lopez, Tomoko Smyth, Rachel McMenamin, John Lyons, Neil Thompson, Victoria Lock, Pietro Taverna, Robert Corringham and Nicola Wallis

  Clin Cancer Res May 15 2012 18 (10 Supplement) B19-B19; DOI:10.1158/1078-0432.MECHRES-B19

  
  
• Poster Presentations

  Abstract B20: A genome-scale RNA interference screen for resistance mechanisms to BRAF inhibition in melanoma

  Steven Whittaker, Eran Hodis, Nikhil Wagle, Jessica Hsiao, Glenn Cowley, David Root and Levi Garraway

  Clin Cancer Res May 15 2012 18 (10 Supplement) B20-B20; DOI:10.1158/1078-0432.MECHRES-B20

  
  
• Poster Presentations

  Abstract B21: Resistance to B-RAF inhibitor is mediated by reactivation of MAPK pathway by FGFR3/Ras signaling in B-RAF V600E mutant melanoma

  Vipin Yadav, Xiaoyi Zhang, Jiangang Liu, Shawn Estrem, Shuyu Dan Li, Xue-Qian Gong, Sean Buchanan, James R. Henry, James J. Starling and Sheng-Bin Peng

  Clin Cancer Res May 15 2012 18 (10 Supplement) B21-B21; DOI:10.1158/1078-0432.MECHRES-B21

  
  
• Poster Presentations

  Abstract B22: Re-expression of miR-200 by natural agents regulates the expression of PTEN and MT1-MMP in pancreatic cancer

  Shadan Ali, Omar Soubani, Azfur Ali, Farah Logna, Philip Philip and Fazlul Sarkar

  Clin Cancer Res May 15 2012 18 (10 Supplement) B22-B22; DOI:10.1158/1078-0432.MECHRES-B22

  
  
• Poster Presentations

  Abstract B23: Reprogramming of the cancer kinome in response to targeted kinase inhibition

  James S. Duncan, Marty W. Whittle, Lee M. Graves and Gary L. Johnson

  Clin Cancer Res May 15 2012 18 (10 Supplement) B23-B23; DOI:10.1158/1078-0432.MECHRES-B23

  
  
• Poster Presentations

  Abstract B24: De novo and acquired resistance to first-line standard therapy in colorectal cancer: from cell lines to metastatic tumors

  Raquel Aloyz, Caroline Rousseau, Zuanel Diaz, Adriana Aguilar-Mahecha, Mark Basik, Luc Bélanger, Marguerite Buchanan, Errol Camlioglu, Andre Constantin, Naciba Benlimame, Suzan McNamara, Zuanel Diaz, Michèle Orain, Ewa Przybytkowski, Alan Spatz, Bernard Têtu, Lawrence Panasci, Gerald Batist, Michel Lebel, Jean-Yves Masson, David Davidson, Eric R. Paquet, Haji Hassan Houssein, Annie Maltais and Therese Gagnon-Kugler

  Clin Cancer Res May 15 2012 18 (10 Supplement) B24-B24; DOI:10.1158/1078-0432.MECHRES-B24

  
  
• Poster Presentations

  Abstract B25: The Effects of PI3K/Akt/mTOR Pathway Inhibitors on a Panel of Non Small Cell Lung Cancer (NSCLC) Cell Lines

  Susan Heavey, Martin Barr, Anthony Davies, Ken O'Byrne and Kathy Gately

  Clin Cancer Res May 15 2012 18 (10 Supplement) B25-B25; DOI:10.1158/1078-0432.MECHRES-B25

  
  
• Poster Presentations

  Abstract B26: Drug-Diagnostic co-development to target FLT3-ITD mutations in chemo-resistant acute myeloid leukemia cells

  Ching-Huai Ko, Chen Ting-Shou, Lin Mei-Wei, Lai Chin-Pen, Kuo Wen-Hsun, Hwang Chrong-Shiong, Wang Ling-Mei and Tsai Jane SC

  Clin Cancer Res May 15 2012 18 (10 Supplement) B26-B26; DOI:10.1158/1078-0432.MECHRES-B26

  
  
• Poster Presentations

  Abstract B28: Downregulation of vimentin confers resistance to the microtubule stabilizing agents peloruside A and laulimalide in 1A9 human ovarian carcinoma cells

  Arun Kanakkanthara, Pisana Rawson, Peter T. Northcote and John H. Miller

  Clin Cancer Res May 15 2012 18 (10 Supplement) B28-B28; DOI:10.1158/1078-0432.MECHRES-B28

  
  
• Poster Presentations

  Abstract B29: TGF-β2 induction in head and neck squamous cell carcinoma cell lines upon treatment with tyrosine kinase inhibitors as a mechanism of acquired resistance

  Emily K. Kleczko, Lydia Heasley and Lynn E. Heasley

  Clin Cancer Res May 15 2012 18 (10 Supplement) B29-B29; DOI:10.1158/1078-0432.MECHRES-B29

  
  
• Poster Presentations

  Abstract B30: Colorectal cancer HCT116 cells resistant toward a novel Aurora kinase inhibitor CYC116: Molecular hallmarks of drug resistance and pharmacologic interventions restoring the drug sensitivity

  Madhusudhan Reddy Kollareddy, Daniella Zheleva, Josef Srovnal, Lenka Radova, Petr Dzubak, Pathik Subhashchandra Brahmkshatriya and Marian Hajduch

  Clin Cancer Res May 15 2012 18 (10 Supplement) B30-B30; DOI:10.1158/1078-0432.MECHRES-B30

  
  
• Poster Presentations

  Abstract B31: HuR cytoplasmic translocation and doxorubicin: how phosphorylation is involved in chemoresistance

  Elisa Latorre, Alessandro Quattrone and Alessandro Provenzani

  Clin Cancer Res May 15 2012 18 (10 Supplement) B31-B31; DOI:10.1158/1078-0432.MECHRES-B31

  
  
• Poster Presentations

  Abstract B32: Impact of Lipid-Substitution on Assembly and Delivery of siRNA by Cationic Polymers

  Hamidreza Montazeri Aliabadi and Hasan Uludag

  Clin Cancer Res May 15 2012 18 (10 Supplement) B32-B32; DOI:10.1158/1078-0432.MECHRES-B32

  
  
• Poster Presentations

  Abstract B33: PTTG1 expression predicts sensitivity to the Src inhibitor Saracatinib in ovarian cancer cell lines

  Ichiro Nakachi, Barbara A. Helfrich, Christopher D. Coldren, Robert S. Stearman, Jessica L. Rice, Amber R. Cornelius and Monique A. Spillman

  Clin Cancer Res May 15 2012 18 (10 Supplement) B33-B33; DOI:10.1158/1078-0432.MECHRES-B33

  
  
• Poster Presentations

  Abstract B34: Bortezomib induces G2-M arrest through ROS-inducible phosphorylation of ATM-CHK1 in human colon cancer cells

  Hong Seung-Woo, Kim Tae Won, Moon Jai-Hee, Hong Yong-Sang, Jin Dong-Hoon, Shin Jae-Sik, Yoon Dok Hyun, Kim Kyu-pyo, Lee Jae-Lyun and Lee Jung Shin

  Clin Cancer Res May 15 2012 18 (10 Supplement) B34-B34; DOI:10.1158/1078-0432.MECHRES-B34

  
  
• Poster Presentations

  Abstract B35: Alternate receptor tyrosine kinases provide protection from FGFR inhibition in HNSCC cells as identified by genome-wide shRNA screening

  Katherine R. Singleton, Aik-Choon Tan, Jihye Kim and Lynn Heasley

  Clin Cancer Res May 15 2012 18 (10 Supplement) B35-B35; DOI:10.1158/1078-0432.MECHRES-B35

  
  
• Poster Presentations

  Abstract B36: Re-activation of protein phosphatase 2A as a multi-target strategy for combating chemotherapy resistance of common cancer types

  Amanpreet Kaur, Anna Cvrljevic and Jukka Westermarck

  Clin Cancer Res May 15 2012 18 (10 Supplement) B36-B36; DOI:10.1158/1078-0432.MECHRES-B36

  
  
• Poster Presentations

  Abstract B37: Monitoring kinome response to EGFR inhibition in triple negative breast cancer

  Martin C. Whittle, James S. Duncan, Lee M. Graves and Gary L. Johnson

  Clin Cancer Res May 15 2012 18 (10 Supplement) B37-B37; DOI:10.1158/1078-0432.MECHRES-B37

  
  
• Poster Presentations

  Abstract B39: Mechanisms of multidrug resistance in AMLs and selective targeting via small molecules

  Chengguo Xing, David Hermanson and Sonia Das

  Clin Cancer Res May 15 2012 18 (10 Supplement) B39-B39; DOI:10.1158/1078-0432.MECHRES-B39

  
  
• Poster Presentations

  Abstract B40: Paracrine interactions through CXCL1/2 chemokines promote breast cancer metastasis and chemoresistance

  Swarnali Acharyya, Thordur Oskarsson, Sakari Vanharanta, Srinivas Malladi, Juliet Kim, Edi Brogi, Larry Norton and Joan Massague

  Clin Cancer Res May 15 2012 18 (10 Supplement) B40-B40; DOI:10.1158/1078-0432.MECHRES-B40

  
  
• Poster Presentations

  Abstract B41: Thymoquinone induces-cell cycle non-specific-cell death in cisplatin-resistant ovarian cancer cell through up-regulation of PTEN expression

  El-Shaimaa A. Arafa and Altaf A. Wani

  Clin Cancer Res May 15 2012 18 (10 Supplement) B41-B41; DOI:10.1158/1078-0432.MECHRES-B41

  
  
• Poster Presentations

  Abstract B42: Heat Shock Protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibition and limits the effectiveness of inhibitors

  Daniele Musiani, Alberto Ramirez Rivera, John David Konda, Simona Pavan, Erica Torchiaro, Martina Olivero and Maria Flavia Di Renzo

  Clin Cancer Res May 15 2012 18 (10 Supplement) B42-B42; DOI:10.1158/1078-0432.MECHRES-B42

  
  
• Poster Presentations

  Abstract B43: Alisertib (MLN8237), an Aurora Kinase A inhibitor, enhances Docetaxel-induced cell death in Upper Gastrointestinal Adenocarcinoma cells

  Vikas Sehdev, Frank Revetta, Abbes Belkhiri, Jeffrey Ecsedy, Alexander Zaika and Wael El-Rifai

  Clin Cancer Res May 15 2012 18 (10 Supplement) B43-B43; DOI:10.1158/1078-0432.MECHRES-B43

  
  
• Poster Presentations

  Abstract B44: Combination treatments of SCLC with ABT-263 and Immunotoxins produces synergistic killing of ABT-263-resistant cells

  Abid R. Mattoo and David J. Fitzgerald

  Clin Cancer Res May 15 2012 18 (10 Supplement) B44-B44; DOI:10.1158/1078-0432.MECHRES-B44

  
  
• Poster Presentations

  Abstract B45: Met-Dependent Positive and Negative Signaling Cascades in Gastric Cancer Cells

  Andrea Z. Lai, Sean Cory, Hong Zhao, Emily S. Bell, Michael Hallett and Morag Park

  Clin Cancer Res May 15 2012 18 (10 Supplement) B45-B45; DOI:10.1158/1078-0432.MECHRES-B45

  
  
• Poster Presentations

  Abstract B46: Targeting tumor-propagating cells in medulloblastoma through inhibition of G2/M cell cycle regulators

  Shirley Markant, Lourdes Adriana Esparza, Kelly Barton, Jesse Sun and Robert Wechsler-Reya

  Clin Cancer Res May 15 2012 18 (10 Supplement) B46-B46; DOI:10.1158/1078-0432.MECHRES-B46

  
  
• Poster Presentations

  Abstract B47: Identification of a novel ALK inhibitor active against Crizotinib-allele resistant mutants

  Jean-Paul Nicolas, Loreley Calvet, Fabrice Vergne, Vincent Leroy, Carlos Garcia-Echeverria, Iris Valtingojer, Laurent Dassencourt, Francoise Herve, Emerson Serres, Laure Delarbre, Meredith Wolfrom, Amanda Lennon, Dietmar Hoffmann and Stephanie Deprets

  Clin Cancer Res May 15 2012 18 (10 Supplement) B47-B47; DOI:10.1158/1078-0432.MECHRES-B47

  
  
• Poster Presentations

  Abstract B48: Sensitization of Hepatocellular Carcinoma Cells to TRAIL by a Novel Aκt/NF-kappaB Signaling Inhibitor

  Hany A. Omar, El-Shaimaa A. Arafa and Jing-Ru Weng

  Clin Cancer Res May 15 2012 18 (10 Supplement) B48-B48; DOI:10.1158/1078-0432.MECHRES-B48

  
  
• Poster Presentations

  Abstract B49: Cancer cell spheroids as a model to study sequential chemotherapy protocols

  Federico Perche and Vladimir P. Torchilin

  Clin Cancer Res May 15 2012 18 (10 Supplement) B49-B49; DOI:10.1158/1078-0432.MECHRES-B49

  
  
• Poster Presentations

  Abstract B50: Per oral nanogel conjugates of activated nucleoside analogs are effective in the treatment of drug-resistant tumors

  Thulani H. Senanayake, Galya Warren, Surender K. Batra, Srikumar M. Raja, Hamid Band and Serguei V. Vinogradov

  Clin Cancer Res May 15 2012 18 (10 Supplement) B50-B50; DOI:10.1158/1078-0432.MECHRES-B50

  
  
• Poster Presentations

  Abstract B52: Design and synthesis of GADD45β agonists for sorefenib-resistance hepatocellular carcinoma cells

  Da-Liang Ou, Hsiang-Hsuan Fan, Chiun Hsu, Ann-Lii Cheng, Cheng-Yi Hsu and Chung-Wai Shiau

  Clin Cancer Res May 15 2012 18 (10 Supplement) B52-B52; DOI:10.1158/1078-0432.MECHRES-B52

  
  
• Poster Presentations

  Abstract B53: Proteasome inhibitor MG132 induces NAG-1 expression through activation of p38 MAPK pathway

  Sachie Shimizu, Harriet Kinyamu, Hiroki Yoshioka, Mitsutoshi Kadowaki, Takashi Watanabe and Thomas Eling

  Clin Cancer Res May 15 2012 18 (10 Supplement) B53-B53; DOI:10.1158/1078-0432.MECHRES-B53

  
  
• Poster Presentations

  Abstract B54: Role of inverted Alu repeats in triggering TMPRSS2-ERG fusions in prostate cancer following irradiation

  Sheetal Singh, Jean P. Cheung, Bay Ho, Andrew Vaughan and Paramita Ghosh

  Clin Cancer Res May 15 2012 18 (10 Supplement) B54-B54; DOI:10.1158/1078-0432.MECHRES-B54

  
  
• Poster Presentations

  Abstract B56: Insights into the role of Epithelial to Mesenchymal transition (EMT) as an important mechanism of drug-resistance to molecular targeted therapies

  Stuart Thomson, Elizabeth Buck, Erica Ullman, Andrew Chau, Peter Mercado, James Bean, Mark Miglarese, David Epstein and John D. Haley

  Clin Cancer Res May 15 2012 18 (10 Supplement) B56-B56; DOI:10.1158/1078-0432.MECHRES-B56

  
  
• Poster Presentations

  Abstract B57: Overcoming Acquired Resistance in Philadelphia-Positive (Ph+) Leukemia

  Mamduh Khateb, Yousef Najajrah, Martin Ruthardt and Jamal Mahajna

  Clin Cancer Res May 15 2012 18 (10 Supplement) B57-B57; DOI:10.1158/1078-0432.MECHRES-B57

  
  
• Poster Presentations

  Abstract B58: The ATP-competitive mammalian target of rapamycin (mTOR) inhibitors suppress proliferation and induce apoptosis in the acquired rapamycin resistant breast cancer cells

  Wu Tzung-Ju, Tsang Chi-Kwan, Zhang Yan-Jie and Zheng X.F. Steven

  Clin Cancer Res May 15 2012 18 (10 Supplement) B58-B58; DOI:10.1158/1078-0432.MECHRES-B58

  
  
• Poster Presentations

  Abstract B59: MET gene copy number related to radiation treatment response and prognosis in breast cancer

  Cynthia Veenstra, Gizeh Pérez-Tenorio, Tommy Fornander, Bo Nordenskjöld and Olle Stål

  Clin Cancer Res May 15 2012 18 (10 Supplement) B59-B59; DOI:10.1158/1078-0432.MECHRES-B59

  
  
• Poster Presentations

  Abstract B60: Overcoming drug resistant cancer by hyaluronic acid based nanogel formulated with anticancer drugs

  Xin Wei, Thulani H. Senanayake and Serguei V. Vinogradov

  Clin Cancer Res May 15 2012 18 (10 Supplement) B60-B60; DOI:10.1158/1078-0432.MECHRES-B60

  
  
• Poster Presentations

  Abstract B61: Picropodophyllin (PPP) increases glucose metabolism and lactate production in paediatric glioblastoma cells

  Anne-Christine Wong Te Fong, Thomas R. Eykyn, Harry G. Parkes, Aleksandra Bielen, Chris Jones, Ian R. Judson, John R. Griffiths, Martin O. Leach and Yuen-Li Chung

  Clin Cancer Res May 15 2012 18 (10 Supplement) B61-B61; DOI:10.1158/1078-0432.MECHRES-B61

  
  
• Poster Presentations

  Abstract B62: Multiple genomic aberrations in BCR-ABL inhibitor-resistant cells lead to sensitivity towards MEK inhibition

  Marie-Claire Wagle, Matthew J. Wongchenko, Vanitha Ramakrishnan, Garret Hampton and Yibing Yan

  Clin Cancer Res May 15 2012 18 (10 Supplement) B62-B62; DOI:10.1158/1078-0432.MECHRES-B62

  
  
• Poster Presentations

  Abstract B63: Heterologous expression of serine palmitoyltransferase-1 alters chemosensitivity and multidrug resistance profile of human cancer cells of different tissue origins

  Tokunbo Yerokun

  Clin Cancer Res May 15 2012 18 (10 Supplement) B63-B63; DOI:10.1158/1078-0432.MECHRES-B63

  
  
• Poster Presentations

  Abstract B64: Development of a novel strategy to overcome drug resistance by targeting ATP citrate lyase and de novo lipogenesis in colorectal cancer cells

  Yunfei Zhou, Federico Tozzi, Ling Xia, Fan Fan, Jia Lu, David Maxwell, Guang Gao, William Bornmann, Zhang Weihua and Lee M Ellis

  Clin Cancer Res May 15 2012 18 (10 Supplement) B64-B64; DOI:10.1158/1078-0432.MECHRES-B64

  
  
• Poster Presentations

  Abstract B65: MicroRNAs in cancer drug resistance and sensitivity

  Jian Zhu

  Clin Cancer Res May 15 2012 18 (10 Supplement) B65-B65; DOI:10.1158/1078-0432.MECHRES-B65

  
  
• Poster Presentations

  Abstract B66: Activation of Wnt/β-catenin signaling enhances TRAIL-dependent apoptosis in human melanoma

  Zachary F. Zimmerman, Andy J. Chien and Randall T. Moon

  Clin Cancer Res May 15 2012 18 (10 Supplement) B66-B66; DOI:10.1158/1078-0432.MECHRES-B66

  
  
• Poster Presentations

  Abstract B67: Increased CXCR4 expression and its nuclear localization are associated with invasion in sorafenib and sunitinib-tolerant hepatocarcinoma models

  Maria Eugenia Riveiro, Armand de Gramont, Eric Raymond, Sandrine Faivre, Maria Serova, Annemilai Tijeras-Raballand, Safi Dokmak, Cindy Neuzillet, Lucile Astorgues-Xerri, Sebastien Albert, Guillemette Huet and Ivan Bieche

  Clin Cancer Res May 15 2012 18 (10 Supplement) B67-B67; DOI:10.1158/1078-0432.MECHRES-B67

  
  
• Poster Presentations

  Abstract B68: Colorectal Cancer in the Setting of Inflammatory Bowel Disease: Role of Hemoglobin

  Michael W. Scaeffer, Amosy E. M'Koma, Joan C. Smith, Billy R. Ballard, Seeley H. Erin, Mary K. Washington, Jeremy L. Norris, Kevin L. Schey, Richard M. Caprioli and Samuel E. Adunyah

  Clin Cancer Res May 15 2012 18 (10 Supplement) B68-B68; DOI:10.1158/1078-0432.MECHRES-B68